Table 1.
Clinical and demographic characteristics of multiple sclerosis patients
| Total MS patients | NEDA | ODA | |
|---|---|---|---|
| n | 22 | 15 | 6 |
| Age at baseline | 36.7 ± 7.42 | 38.0 ± 7.53 | 33.8 ± 7.47 |
| Gender (% female) | 15/22 (68.2%) | 11/15 (73.3%) | 3/6 (50.0%) |
| Disease duration (y) | 4.18 ± 4.72 | 4.60 ± 5.12 | 3.67 ± 4.13 |
| Prior treatment | |||
| Naïve | 15 | 11 | 3 |
| IFN‐β | 4 | 3 | 1 |
| Fingolimod | 1 | – | 1 |
| Aubagio | 1 | – | 1 |
| Othersa | 1 | 1 | – |
| Baseline ARR | 1.14 ± 0.62 | 0.99 ± 0.48 | 1.39 ± 0.83 |
| Relapses during the previous year | 1.50 ± 0.91 | 1.33 ± 0.90 | 1.83 ± 0.98 |
| Relapses after 12 mo of DMF treatment | 0.15 ± 0.37 | – | 0.50 ± 0.55 |
| Baseline EDSS | 2.34 ± 1.47 | 2.27 ± 1.58 | 2.75 ± 1.21 |
| EDSS after 12 mo of DMF treatment | 2.26 ± 1.93 | 2.04 ± 1.84 | 3.17 ± 1.97 |
| Baseline T2 lesions | |||
| <9 T2 lesions | 5/22 (22.7%) | 4/15 (26.7%) | 1/5 (20.0%) |
| >9 T2 lesions | 17/22 (77.3%) | 11/15 (73.3%) | 5/6 (80.0%) |
| New T2 lesions after 12 mo of treatment (%) | 4/21 (19.04%) | – | 4/6 (66.7%) |
| Presence of gadolinium‐enhancing lesions at baseline | 10/21 (47.6%) | 6/15 (40.0%) | 4/6 (66.7%) |
| New gadolinium‐enhancing lesions after 12 mo of DMF treatment | 1/21 (0.05%) | – | 1/6 (16.7%) |
Abbreviations: ARR: annual relapse rate; EDSS: Expanded Disability Status Scale; NEDA: no evidence of disease activity; ODA: ongoing disease activity.
a
Others: cell therapy clinical trial.